David Lebovitz
Stock Analyst at Citigroup
(3.27)
# 976
Out of 4,784 analysts
94
Total ratings
65.62%
Success rate
7.48%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Lebovitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $338 → $351 | $268.46 | +30.75% | 31 | Mar 21, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $378 → $469 | $327.87 | +43.04% | 4 | Feb 27, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Neutral | $81 → $82 | $71.44 | +14.78% | 3 | Feb 20, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Buy | $70 → $74 | $34.73 | +113.07% | 2 | Nov 14, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $37 → $38 | $45.99 | -17.37% | 1 | May 9, 2024 | |
| PTCT PTC Therapeutics | Downgrades: Sell | $29 → $17 | $54.24 | -68.66% | 5 | Oct 27, 2023 | |
| BPMC Blueprint Medicines | Maintains: Equal-Weight | $111 → $92 | $88.72 | +3.70% | 6 | Feb 1, 2022 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $57 → $54 | $54.80 | -1.46% | 5 | Aug 4, 2021 | |
| IONS Ionis Pharmaceuticals | Maintains: Underweight | $38 → $35 | $31.15 | +12.36% | 6 | May 6, 2021 | |
| MGNX MacroGenics | Maintains: Underweight | $16 → $17 | $1.26 | +1,249.21% | 11 | Apr 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $11 | $1.41 | +680.14% | 7 | Feb 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $194 → $199 | $154.68 | +28.65% | 11 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $510 → $480 | $4.16 | +11,438.46% | 2 | Nov 3, 2020 |
Alnylam Pharmaceuticals
Mar 21, 2025
Maintains: Buy
Price Target: $338 → $351
Current: $268.46
Upside: +30.75%
Madrigal Pharmaceuticals
Feb 27, 2025
Maintains: Buy
Price Target: $378 → $469
Current: $327.87
Upside: +43.04%
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Neutral
Price Target: $81 → $82
Current: $71.44
Upside: +14.78%
Crinetics Pharmaceuticals
Nov 14, 2024
Maintains: Buy
Price Target: $70 → $74
Current: $34.73
Upside: +113.07%
Mirum Pharmaceuticals
May 9, 2024
Maintains: Buy
Price Target: $37 → $38
Current: $45.99
Upside: -17.37%
PTC Therapeutics
Oct 27, 2023
Downgrades: Sell
Price Target: $29 → $17
Current: $54.24
Upside: -68.66%
Blueprint Medicines
Feb 1, 2022
Maintains: Equal-Weight
Price Target: $111 → $92
Current: $88.72
Upside: +3.70%
Rhythm Pharmaceuticals
Aug 4, 2021
Maintains: Overweight
Price Target: $57 → $54
Current: $54.80
Upside: -1.46%
Ionis Pharmaceuticals
May 6, 2021
Maintains: Underweight
Price Target: $38 → $35
Current: $31.15
Upside: +12.36%
MacroGenics
Apr 30, 2021
Maintains: Underweight
Price Target: $16 → $17
Current: $1.26
Upside: +1,249.21%
Feb 22, 2021
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $1.41
Upside: +680.14%
Nov 13, 2020
Maintains: Overweight
Price Target: $194 → $199
Current: $154.68
Upside: +28.65%
Nov 3, 2020
Maintains: Overweight
Price Target: $510 → $480
Current: $4.16
Upside: +11,438.46%